Karen Gulenchyn

Gulenchyn

Dr. Gulenchyn is the Integrated Chief, Department of Nuclear Medicine at Hamilton Health Sciences and St. Joseph’s Healthcare  in Hamilton, Ontario.  Recognizing the considerable capacity of Hamilton, with a nuclear reactor, 2 cyclotrons and an extensive suite of GMP labs,  to participate in the burgeoning field of Molecular Imaging, Dr. Gulenchyn has worked to move one of Canada’s first positron emission imaging programs into the realm of clinical and translational medicine in of cancer and cardiology.

Dr. Gulenchyn has participated on the boards of many professional societies and in an advisory capacity to a number of federal and provincial governmental agencies.  She has been a member of the Ontario PET Steering Committee from 2002 to 2010, and has worked in both the design and implementation of Ontario’s PET trials and registries.  These trials were designed to fill the gaps identified in the evidence for the clinical utility of FDG PET and to support future analyses through linkages with provincial databases.

Leveraging the knowledge and skills acquired through this work  has resulted in the development of a molecular imaging program which this year will begin to conduct Phase 1 radiopharmaceutical trials.

Key Publications:

Gulenchyn KY, Yao X, Asa SL, Singh S, Law C.  Radionuclide therapy in neuroendocrine tumours:  A systematic review.  Clinical Oncology 2012 24: 294-308

Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Gu C-S, Kuruvilla MS, Cline KJ, Julian JA, Evans WK, Levine MN.  Positron Emission Tomography-Computed Tomography compared with invasive mediastinal staging in non-small cell lung cancer:  results of mediastinal staging in early lung positron emission tomography trial.  J Thorac Oncol 2011 6:  1367-72

Moulton C-A, Gu C-S, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith RJ, Jalink DW, Husein M, Serrano PE, Hendler A, Haider M, Ruo L, Gulenchyn KY, Finch T, Julian J, Levine MN, Gallinger S.  Impact of PET imaging prior to liver resection for colorectal cancer liver metastases: a randomized clinical trial.  JAMA 2014  311:1863-9